Methods of treating cancers with antagonistic anti-PD-1 antibodies
The present invention relates to methods of treating cancers with antagonistic anti-PD-1 antibodies, formulations of the antagonistic anti-PD-1 antibodies and drug products of the anti-PD-1 antibodies.
1. A method of treating a cancer, comprising administering to a subject diagnosed with the cancer a dose of between about 240 mg and about 480 mg of an antagonistic human anti-PD-1 antibody or an antigen binding fragment thereof that comprises
a heavy chain of SEQ ID NO: 9 and a light chain of SEQ ID NO: 10, thereby treating the cancer,
wherein the cancer is a solid tumor that is metastatic or unresectable.
2. The method of claim 1 , wherein the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof is administered once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every six weeks.
3. The method of claim 1 , wherein the antagonistic anti-PD- 1 antibody or the antigen binding fragment thereof is administered
a) at a dosage of about 240 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every six weeks;
b) at the dosage of about 240 mg once every two weeks;
c) at the dosage of about 240 mg once every three weeks;
d) at the dosage of about 240 mg once every four weeks;
e) at the dosage of about 240 mg once every five weeks;
f) at the dosage of about 240 mg once every six weeks;
g) at a dosage of about 480 mg once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every six weeks;
h) at the dosage of about 480 mg once every two weeks;
i) at the dosage of about 480 mg once every three weeks;
j) at the dosage of about 480 mg once every four weeks;
k) at the dosage of about 480 mg once every five weeks; or
l) at the dosage of about 480 mg once every six weeks.
4. The method of claim 3 , wherein the cancer is selected from the group consisting of a lung cancer, a non-small cell lung cancer (NSCLC), a melanoma, a head and neck cancer, a bladder cancer, a gastrointestinal cancer, a gastric cancer, a gastro-esophageal junction cancer, an esophageal cancer, a liver cancer, a colorectal cancer (CRC), a colon cancer, a gallbladder cancer, a biliary tract cancer, an ovarian cancer, a fallopian tube cancer, a cervical cancer, a peritoneal cancer, an endometrial cancer, a small cell lung cancer (SCLC), a breast cancer, a pancreatic cancer, a renal cell carcinoma, a liver cancer, a Merkel cell carcinoma, a primary mediastinal B-cell lymphoma (PMBCL), a Hodgkin's lymphoma, a non-Hodgkin's lymphoma, a large diffuse B-cell cell lymphoma (DLBLC), a multiple myeloma, a glioblastoma, an urothelial cancer, a salivary cancer, a mesothelioma, an anal cancer, a prostate cancer, a basal cell carcinoma and an advanced cutaneous squamous cell carcinoma (CSCC), or any combination thereof.
5. The method of claim 4 , wherein the subject is PD-1 axis naïve.
6. The method of claim 4 , wherein the subject has received one, two, three or more prior therapeutics to treat the cancer.
7. The method of claim 6 , wherein the one, two, three or more prior therapeutics to treat the cancer are an anti-CTLA4 antibody, ipilimumab, BRAF/MEK inhibitor, chemotherapy or interferon alpha, or any combination thereof.
8. The method of claim 6 , wherein the subject is resistant, refractory or resistant and refractory to the one, two, three or more prior therapeutics to treat the cancer, or any combination thereof.
9. The method of claim 8 , wherein the one, two, three or more prior therapeutics to treat the cancer are an anti-CTLA4 antibody, ipilimumab, BRAF/MEK inhibitor, chemotherapy or interferon alpha, or any combination thereof.
10. The method of claim 4 , wherein the cancer is PD-L1 positive.
11. The method of claim 10 , wherein the cancer is PD-L1 high.
12. The method of claim 4 , wherein PD-L1 expression in the cancer is undetermined.
13. The method of claim 4 , wherein the cancer expresses a mutant BRAF.
14. The method of claim 13 , wherein the mutant BRAF comprises a V600E mutation.
15. The method of claim 4 , wherein the cancer expresses a wild-type BRAF.
16. The method of claim 4 , wherein the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof is
a) administered or provided for administration in a pharmaceutical composition comprising between about 10 mg/ml to about 30 mg/ml of the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof, about 10 mM histidine, about 8.0% (w/v) sucrose, about 0.04% (w/v) polysorbate-20 and about 20 ug/ml EDTA at pH 6.5;
b) administered or provided for administration in a pharmaceutical composition comprising about 10 mg/ml of the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof, about 10 mM histidine, about 8.0% (w/v) sucrose, about 0.04% (w/v) polysorbate-20 and about 20 ug/ml EDTA at pH 6.5;
c) administered or provided for administration in a pharmaceutical composition comprising about 30 mg/ml of the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof, about 10 mM histidine, about 8.0% (w/v) sucrose, about 0.04% (w/v) polysorbate-20 and about 20 ug/ml EDTA at pH 6.5;
d) provided for administration as a lyophilized formulation comprising between about 90 mg and about 240 mg of the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof and one or more pharmaceutically acceptable excipients;
e) provided for administration as a lyophilized formulation comprising about 90 mg of the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof and one or more pharmaceutically acceptable excipients; or
f) provided for administration as a lyophilized formulation comprising about 240 mg of the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof and one or more pharmaceutically acceptable excipients.
17. The method of claim 16 , wherein the lyophilized formulation of d), e) and/or f), once reconstituted, comprises about 30 mg/ml of the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof, about 10 mM histidine, about 8.0% (w/v) sucrose, about 0.04% (w/v) polysorbate-20 and about 20 ug/ml EDTA at pH 6.5.
18. The method of claim 4 , wherein the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof is administered by an intravenous infusion.
19. The method of claim 4 , wherein the antagonistic anti-PD-1 antibody or the antigen binding fragment thereof is administered by a subcutaneous injection.
20. The method of claim 4 , wherein the method achieves an overall response rate (ORR) of at least about 15% in a group of subjects diagnosed with the cancer.
21. The method of claim 20 , wherein the ORR of at least about 15% is achieved after a median duration of treatment of about 1 ½ months or more.
22. The method of claim 20 , wherein the method achieves an ORR of at least about 19% in the group of subjects diagnosed with the cancer.
23. The method of claim 4 , wherein the cancer is the non-small cell lung cancer (NSCLC).
24. The method of claim 23 , wherein the method achieves an ORR of at least about 30% in a group of subjects diagnosed with PD-L1 high NSCLC or an ORR of at least about 25% in a group of subjects whose PD-L1 expression in the cancer is undetermined.
25. The method of claim 24 , wherein the method achieves an ORR of at least about 35% in the group of subjects diagnosed with PD-L1 high NSCLC.
26. The method of claim 4 , wherein the cancer is the melanoma.
27. The method of claim 26 , wherein the method achieves an ORR of at least about 25% in a group of subjects diagnosed with the melanoma.
28. The method of claim 27 , wherein the melanoma is a non-uveal melanoma.
29. The method of claim 28 , wherein the method achieves an ORR of at least about 30% in a group of subjects diagnosed with the non-uveal melanoma.
30. The method of claim 4 , wherein the CRC is a microsatellite instability-high (MSI-H) CRC or a mismatch repair-deficient (dMMR) CRC, or a combination thereof.
31. The method of claim 30 , wherein the CRC is a stage II CRC or a stage III CRC.
32. The method of claim 1 , wherein administration of the anti-PD-1 antibody at a dosage of from about 240 mg to about 480 mg results in decreased grade three or higher adverse events compared to administration of the anti-PD-1 antibody at a dosage of 800 mg.
33. The method of claim 1 , wherein administration of the anti-PD-1 antibody at a dosage of from about 240 mg to about 480 mg results in an increased response rate compared to administration of the anti-PD-1 antibody at a dosage 80 mg).
34. A method of treating a cancer, comprising administering to a subject diagnosed with the cancer a dose of between about 240 mg and about 480 mg of an antagonistic human anti-PD-1 antibody or an antigen binding fragment thereof that comprises
a heavy chain of SEQ ID NO: 9 and a light chain of SEQ ID NO: 10,
thereby treating the cancer,
wherein the subject has previously received or was ineligible for standard treatment options.